Why patients should be involved in evaluating novel drugs in multiple myeloma

Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France discusses the role of the patient in the debate around the access to and affordability of novel drugs in multiple myeloma (MM). Prof Harousseau argues that patients should be aware of novel drugs and their benefit, which may not always be significant. He further argues that like doctors, patients should take into consideration the cost-effectiveness ratio and further, that patients should be involved in the evaluation of novel drugs.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.